Studies on the immunogenicity of hCEA in a transgenic mouse model.
OBJECTIVE
Immunization protocols in mice have shown that the tumor-associated antigen hCEA could be a target for active immunization; however, human CEA is foreign to mice. Success may depend in part on a simple anti-xenoresponse. Using hCEA-transfected syngeneic tumor cells in hCEA-transgenic mice should bypass this problem and allow testing for new vaccination strategies.


METHODS
We established a hCEA transgenic model of the haplotype H2(d), which may differ from other haplotypes in cytokine production and in effectiveness of antigen presentation, and tested two vaccination protocols in wild-type and transgenic mice.


RESULTS
Syngeneic wild-type mice built up an immune response with high antibody titers; only 65% of animals developed solid tumors after tumor challenge. In contrast, hCEA-transgenic mice developed no antibody response and accepted the tumor in more than 90% of cases, thus demonstrating the role of human CEA as a foreign antigen. Accordingly, active immunization using tumor lysate or lymphocytes loaded with hCEA resulted in a CTL response and tumor-rejection in up to 80% of wild-type mice. hCEA-transgenic mice could be induced with both immunization protocols to build up a CTL response, although the number of CTL were much lower and the cytotoxic response weaker than in wild-type mice. In vivo hCEA-transgenic mice rejected hCEA-positive tumors only after immunization with the tumor lysate in about 60% whereas there was no rejection of tumors after immunization with the human hCEA-loaded autologous lymphocytes.


CONCLUSIONS
The findings clearly show the importance of transgenic models when testing the effects of immunization towards human tumor associated antigens such as hCEA because results differ in wild-type and transgenic mice.
Muders
M
M
Institute for Surgical Research, Klinikum Grosshadern, University of Munich, Marchioninistrasse 27, 81366 Munich, Germany.
Ghoreschi
K
K
Suckfuell
M
M
Zimmermann
W
W
Enders
G
G
D000818:Animals; D000912:Antibodies, Neoplasm; D000917:Antibody Formation; D002272:Carcinoembryonic Antigen / Q000276:immunology*; D007939:Leukemia L1210; D051379:Mice; D008811:Mice, Inbred DBA; D008822:Mice, Transgenic; D009369:Neoplasms / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014407:Tumor Cells, Cultured; D014611:Vaccination
D000912:Antibodies, Neoplasm; D002272:Carcinoembryonic Antigen